<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28754299</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1678-4405</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Season>Oct-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]</Title>
          <ISOAbbreviation>Braz J Microbiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat.</ArticleTitle>
        <Pagination>
          <StartPage>617</StartPage>
          <EndPage>628</EndPage>
          <MedlinePgn>617-628</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bjm.2017.06.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1517-8382(16)31135-2</ELocationID>
        <Abstract>
          <AbstractText>Neisseria gonorrhoeae is the agent of gonorrhea, a sexually transmitted infection with an estimate from The World Health Organization of 78 million new cases in people aged 15-49 worldwide during 2012. If left untreated, complications may include pelvic inflammatory disease and infertility. Antimicrobial treatment is usually effective; however, resistance has emerged successively through various molecular mechanisms for all the regularly used therapeutic agents throughout decades. Detection of antimicrobial susceptibility is currently the most critical aspect for N. gonorrhoeae surveillance, however poorly structured health systems pose difficulties. In this review, we compiled data from worldwide reports regarding epidemiology and antimicrobial resistance in N. gonorrhoeae, and highlight the relevance of the implementation of surveillance networks to establish policies for gonorrhea treatment.</AbstractText>
          <CopyrightInformation>Copyright © 2017 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Costa-Lourenço</LastName>
            <ForeName>Ana Paula Ramalho da</ForeName>
            <Initials>APRD</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Microbiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barros Dos Santos</LastName>
            <ForeName>Késia Thaís</ForeName>
            <Initials>KT</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Microbiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moreira</LastName>
            <ForeName>Beatriz Meurer</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Microbiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fracalanzza</LastName>
            <ForeName>Sergio Eduardo Longo</ForeName>
            <Initials>SEL</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Microbiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonelli</LastName>
            <ForeName>Raquel Regina</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Microbiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: raquel.bonelli@micro.ufrj.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016456">Historical Article</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>07</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Braz J Microbiol</MedlineTA>
        <NlmUniqueID>101095924</NlmUniqueID>
        <ISSNLinking>1517-8382</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="Y">Drug Resistance, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006069" MajorTopicYN="N">Gonorrhea</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009344" MajorTopicYN="N">Neisseria gonorrhoeae</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Neisseria gonorrhoeae</Keyword>
        <Keyword MajorTopicYN="N">Resistance mechanisms</Keyword>
        <Keyword MajorTopicYN="N">Surveillance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28754299</ArticleId>
        <ArticleId IdType="pmc">PMC5628311</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bjm.2017.06.001</ArticleId>
        <ArticleId IdType="pii">S1517-8382(16)31135-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chan P.A., Robinette A., Montgomery M. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4913006</ArticleId>
            <ArticleId IdType="pubmed">27366021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ison C.A.  Biology of Neisseria gonorrhoeae and the clinical picture of infection. In: Gross G.E., Tyring S.K., editors. Sexually Transmitted Infections and Sexually Transmitted Diseases. Springer; Berlin Heidelberg: 2011. pp. 77–90.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization; Geneva: 2016. WHO Guidelines for the Treatment of Neisseria gonorrhoeae.http://www.ncbi.nlm.nih.gov/books/NBK379221/</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . CDC; A Atlanta: 2016. Gonococcal Isolates Surveillance Project Protocol 2016.http://www.cdc.gov/std/gisp/gisp-protocol-many-2016.pdf Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . 2014. Sexually Transmitted Disease Surveillance, National Profile.https://www.cdc.gov/std/stats14/gonorrhea.htm Accessed 01.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . 2015. Sexually Transmitted Diseases Treatment Guidelines.http://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . 2014. Gonococcal Isolates Surveillance Project Profiles.http://www.cdc.gov/std/gisp2014/gisp-2014-text-fig-tables.pdf Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Grad Y.H., Kirkcaldy R.D., Trees D. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis. 2014;14(3):220–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4030102</ArticleId>
            <ArticleId IdType="pubmed">24462211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canada PHA of, Canada PHA of . 2014. National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae – Annual Summary.https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-surveillance-antimicrobial-susceptibilities-neisseria-gonorrhoeae-annual-summary-2014.html Published 05.02.16, Accessed 01.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>ECDC . ECDC; Stockholm: 2016. Gonococcal Antimicrobial Susceptibility Surveillance in Europe 2014.http://ecdc.europa.eu/en/publications/Publications/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2014.pdf Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>EUCAST . EUCAST; 2017. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 7.0.http://www.eucast.org/clinical_breakpoints/ Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>CLSI . CLSI; Wayne: 2017. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Seventh Informational Supplement M100-S27.</Citation>
        </Reference>
        <Reference>
          <Citation>Lahra M.M., Enriquez R.P. National Neisseria Network. Australian Gonococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2017;41(1) E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28385139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahra M.M., Enriquez R.P. Australian Gonococcal Surveillance Programme, 1 January to 31 March 2015. Commun Dis Intell Q Rep. 2015;39(2):E297–E298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26234265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahra M.M. WHO Western Pacific and South East Asian Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2010. Commun Dis Intell Q Rep. 2012;36(1):95–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23153085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . WHO; 2012. Baseline Report on Global Sexually Transmitted Infection Surveillance.http://www.who.int/reproductivehealth/publications/rtis/9789241505895/en/ Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Ndowa F.J., Francis J.M., Machiha A., Faye-Kette H., Fonkoua M.C. Gonococcal antimicrobial resistance: perspectives from the African region. Sex Transm Infect. 2013;89(suppl 4):iv11–iv15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24243873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO | Progress report of the implementation of the global strategy for prevention and control of sexually transmitted infections: 2006–2015. WHO. http://www.who.int/reproductivehealth/publications/rtis/progress-report-stis-strategy/en/ Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Dillon J.-A.R., Trecker M.A., Thakur S.D. Gonococcal Antimicrobial Surveillance Program Network in Latin America and Caribbean 1990–2011. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect. 2013;89(suppl 4):iv36–iv41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24243878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Notícias B da S Blog, Saúde, Ministério. Pesquisa revela altas taxas de resistência aos antimicrobianos no país. Blog da Saúde. http://www.blog.saude.gov.br/gx0dy8 Accessed 01.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST) | Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais. http://www.aids.gov.br/publicacao/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infecc Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>DST no Brasil | Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais. http://www.aids.gov.br/pagina/dst-no-brasil Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Starnino S., GASP-LAC Working Group, Galarza P. Retrospective analysis of antimicrobial susceptibility trends (2000–2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex Transm Dis. 2012;39(10):813–821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23001269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belda Junior W., Velho P.E.N.F., Arnone M., Fagundes L.J. Emergence of fluoroquinolone-resistant Neisseria gonorrhoeae in São Paulo, Brazil. Braz J Microbiol. 2007;38(2):293–295.</Citation>
        </Reference>
        <Reference>
          <Citation>Uehara A.A., Amorin E.L.T., Ferreira M. de F. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae isolates from Brazil. J Clin Microbiol. 2011;49(12):4208–4212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3232978</ArticleId>
            <ArticleId IdType="pubmed">21976763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa L.M.B., Pedroso E.R.P., Vieira Neto V., Souza V.C.P., Teixeira M.J.B. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from patients attending a public referral center for sexually transmitted diseases in Belo Horizonte, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2013;46(3):304–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23856869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilina E.N., Oparina N.Y., Shitikov E.A., Borovskaya A.D., Govorun V.M. Molecular surveillance of clinical Neisseria gonorrhoeae isolates in Russia. J Clin Microbiol. 2010;48(10):3681–3689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953076</ArticleId>
            <ArticleId IdType="pubmed">20660213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Dillon J.-A.R. Review and international recommendation of methods for typing Neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev. 2011;24(3):447–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131056</ArticleId>
            <ArticleId IdType="pubmed">21734242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidovic S., Caron C., Taheri A. Using crude whole-genome assemblies of Neisseria gonorrhoeae as a platform for strain analysis: clonal spread of gonorrhea infection in Saskatchewan, Canada. J Clin Microbiol. 2014;52(10):3772–3776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4187769</ArticleId>
            <ArticleId IdType="pubmed">25056324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bignell C., Unemo M., European STI Guidelines Editorial Board 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24400344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonorrhoea – Australian STI Management Guidelines. http://sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea Accessed 01.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamasuna R., Yasuda M., Ishikawa K. The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012–2013. J Infect Chemother Off J Jpn Soc Chemother. 2015;21(5):340–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25727286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Government of Canada PHA of C. Canadian Guidelines on Sexually Transmitted Infections – Public Health Agency of Canada. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php Published 01.02.13, Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Unemo M., Shafer W.M. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci. 2011;1230:E19–E28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4510988</ArticleId>
            <ArticleId IdType="pubmed">22239555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Nicholas R.A. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7(12):1401–1422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3629839</ArticleId>
            <ArticleId IdType="pubmed">23231489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Shafer W.M. Future treatment of gonorrhea – novel emerging drugs are essential and in progress? Expert Opin Emerg Drugs. 2015;20(3):357–360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4550495</ArticleId>
            <ArticleId IdType="pubmed">25907334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kampmeier R.H. Introduction of sulfonamide therapy for gonorrhea. Sex Transm Dis. 1983;10(2):81–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6362039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell D.J. Gonorrhoea in N. Africa and central Mediterranean. Br Med J. 1944;2(4357):44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2285755</ArticleId>
            <ArticleId IdType="pubmed">20785525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson S.R., Morse S.A. Antibiotic resistance in Neisseria gonorrhoeae: genetics and mechanisms of resistance. Sex Transm Dis. 1988;15(4):217–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3147526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csonka G.W., Knight G.J. Therapeutic trial of trimethoprim as a potentiator of sulphonamides in gonorrhoea. Br J Vener Dis. 1967;43(3):161–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1047874</ArticleId>
            <ArticleId IdType="pubmed">5233504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Averett D.R., Roth B., Burchall J.J., Baccanari D.P. Dihydrofolate reductase from Neisseria sp. Antimicrob Agents Chemother. 1979;15(3):428–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC352677</ArticleId>
            <ArticleId IdType="pubmed">111611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence A., Phillips I., Nicol C. Various regimens of trimethoprim-sulfamethoxazole used in the treatment of gonorrhea. J Infect Dis. 1973;128(suppl):673–678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4202208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis D.A. The Gonococcus fights back: is this time a knock out? Sex Transm Infect. 2010;86(6):415–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20656721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Slyke C.J., Arnold R.C., Buchholtz M. Penicillin therapy in sulfonamide-resistant gonorrhea in men. Am J Public Health Nations Health. 1943;33(12):1392–1394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1527694</ArticleId>
            <ArticleId IdType="pubmed">18015911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin J.E., Lester A., Price E.V., Schmale J.D. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955–1969. J Infect Dis. 1970;122(5):459–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4990947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zapun A., Contreras-Martel C., Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev. 2008;32(2):361–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18248419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparling P.F., Sarubbi F.A., Blackman E. Inheritance of low-level resistance to penicillin, tetracycline, and chloramphenicol in Neisseria gonorrhoeae. J Bacteriol. 1975;124(2):740–749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC235963</ArticleId>
            <ArticleId IdType="pubmed">810479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedarovich A., Cook E., Tomberg J., Nicholas R.A., Davies C. Structural effect of the Asp345a insertion in penicillin-binding protein 2 from penicillin-resistant strains of Neisseria gonorrhoeae. Biochemistry (Mosc) 2014;53(48):7596–7603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4263433</ArticleId>
            <ArticleId IdType="pubmed">25403720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito M., Deguchi T., Mizutani K.-S. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother. 2005;49(1):137–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC538884</ArticleId>
            <ArticleId IdType="pubmed">15616287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindberg R., Fredlund H., Nicholas R., Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother. 2007;51(6):2117–2122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1891421</ArticleId>
            <ArticleId IdType="pubmed">17420216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiley D.M., Limnios E.A., Ray S., Sloots T.P., Tapsall J.W. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother. 2007;51(9):3111–3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2043202</ArticleId>
            <ArticleId IdType="pubmed">17591846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandori M., Barry P.M., Wu A. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother. 2009;53(9):4032–4034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2737862</ArticleId>
            <ArticleId IdType="pubmed">19546370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S.-G., Lee H., Jeong S.H. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother. 2010;65(4):669–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2837549</ArticleId>
            <ArticleId IdType="pubmed">20093260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohnishi M., Watanabe Y., Ono E. Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother. 2010;54(3):1060–1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826007</ArticleId>
            <ArticleId IdType="pubmed">20028823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohnishi M., Golparian D., Shimuta K. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538–3545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122416</ArticleId>
            <ArticleId IdType="pubmed">21576437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropp P.A., Hu M., Olesky M., Nicholas R.A. Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2002;46(3):769–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC127492</ArticleId>
            <ArticleId IdType="pubmed">11850260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olesky M., Hobbs M., Nicholas R.A. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2002;46(9):2811–2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC127413</ArticleId>
            <ArticleId IdType="pubmed">12183233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maier T.W., Zubrzycki L., Coyle M.B., Chila M., Warner P. Genetic analysis of drug resistance in Neisseria gonorrhoeae: production of increased resistance by the combination of two antibiotic resistance loci. J Bacteriol. 1975;124(2):834–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC235974</ArticleId>
            <ArticleId IdType="pubmed">810484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olesky M., Zhao S., Rosenberg R.L., Nicholas R.A. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol. 2006;188(7):2300–2308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1428387</ArticleId>
            <ArticleId IdType="pubmed">16547016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagman K.E., Pan W., Spratt B.G., Balthazar J.T., Judd R.C., Shafer W.M. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiol Read Engl. 1995;141(Pt 3):611–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7711899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner D.M., Shafer W.M., Jerse A.E. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol. 2008;70(2):462–478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2602950</ArticleId>
            <ArticleId IdType="pubmed">18761689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarantonelli L., Borthagaray G., Lee E.H., Veal W., Shafer W.M. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae. J Antimicrob Chemother. 2001;47(5):651–654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11328778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohneck E.A., Zalucki Y.M., Johnson P.J.T. A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae. mBio. 2011;2(5)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3175627</ArticleId>
            <ArticleId IdType="pubmed">21933917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S., Tobiason D.M., Hu M., Seifert H.S., Nicholas R.A. The penC mutation conferring antibiotic resistance in Neisseria gonorrhoeae arises from a mutation in the PilQ secretin that interferes with multimer stability. Mol Microbiol. 2005;57(5):1238–1251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2673695</ArticleId>
            <ArticleId IdType="pubmed">16101998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashford W.A., Golash R.G., Hemming V.G. Penicillinase-producing. Lancet Lond Engl. 1976;2(7987):657–658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">60519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips I. Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet Lond Engl. 1976;2(7987):656–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">60518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Percival A., Rowlands J., Corkill J.E. Penicillinase-producing gonococci in Liverpool. Lancet Lond Engl. 1976;2(8000):1379–1382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">63850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagotto F., Aman A.T., Ng L.K., Yeung K.H., Brett M., Dillon J.A. Sequence analysis of the family of penicillinase-producing plasmids of Neisseria gonorrhoeae. Plasmid. 2000;43(1):24–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10610817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller E.E., Fayemiwo S.A., Lewis D.A. Characterization of a novel β-lactamase-producing plasmid in Neisseria gonorrhoeae: sequence analysis and molecular typing of host gonococci. J Antimicrob Chemother. 2011;66(7):1514–1517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21525021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung K.H., Dillon J.R., Pauzé M., Wallace E. A novel 4.9-kilobase plasmid associated with an outbreak of penicillinase-producing Neisseria gonorrhoeae. J Infect Dis. 1986;153(6):1162–1165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3009647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Embden J.D., Dessens-Kroon M., Van Klingeren B. A new beta-lactamase plasmid in Neisseria gonorrhoeae. J Antimicrob Chemother. 1985;15(2):247–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2984155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouby A., Bourg G., Ramuz M. Previously undescribed 6.6-kilobase R plasmid in penicillinase-producing Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1986;29(6):1095–1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC180507</ArticleId>
            <ArticleId IdType="pubmed">3089144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brett M. A novel gonococcal beta-lactamase plasmid. J Antimicrob Chemother. 1989;23(4):653–654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2501272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trembizki E., Buckley C., Lawrence A., Lahra M., Whiley D., GRAND Study Investigators  Characterization of a novel Neisseria gonorrhoeae penicillinase-producing plasmid isolated in Australia in 2012. Antimicrob Agents Chemother. 2014;58(8):4984–4985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136051</ArticleId>
            <ArticleId IdType="pubmed">24890595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev MMBR. 2001;65(2):232–260. second page, table of contents.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC99026</ArticleId>
            <ArticleId IdType="pubmed">11381101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu M., Nandi S., Davies C., Nicholas R.A. High-level chromosomally mediated tetracycline resistance in Neisseria gonorrhoeae results from a point mutation in the rpsJ gene encoding ribosomal protein S10 in combination with the mtrR and penB resistance determinants. Antimicrob Agents Chemother. 2005;49(10):4327–4334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1251527</ArticleId>
            <ArticleId IdType="pubmed">16189114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC. Tetracycline-resistant Neisseria gonorrhoeae – Georgia, Pennsylvania, New Hampshire. https://www.cdc.gov/mmwr/preview/mmwrhtmL/00000611.htm Accessed 02.06.17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3929060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morse S.A., Johnson S.R., Biddle J.W., Roberts M.C. High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother. 1986;30(5):664–670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC176510</ArticleId>
            <ArticleId IdType="pubmed">3099640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pachulec E., van der Does C. Conjugative plasmids of Neisseria gonorrhoeae. PLoS ONE. 2010;5(4):e9962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848598</ArticleId>
            <ArticleId IdType="pubmed">20376355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC . 1989. Sexually Transmitted Diseases Treatment Guidelines.https://www.cdc.gov/mmwr//preview/mmwrhtmL/00001459.htm Accessed 02.06.17.</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson J.E., Hobbs M.M., Biswas G.D., Sparling P.F. Opposing selective forces for expression of the gonococcal lactoferrin receptor. Mol Microbiol. 2003;48(5):1325–1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12787359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gransden W.R., Warren C.A., Phillips I., Hodges M., Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet Lond Engl. 1990;335(8680):51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1967354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birley H., McDonald P., Carey P., Fletcher J. High level ciprofloxacin resistance in Neisseria gonorrhoeae. Genitourin Med. 1994;70(4):292–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1195260</ArticleId>
            <ArticleId IdType="pubmed">7959720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapsall J.W., Limnios E.A., Thacker C. High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sex Transm Dis. 1995;22(5):310–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7502185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deguchi T., Saito I., Tanaka M. Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones. Sex Transm Dis. 1997;24(5):247–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9153731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(suppl 2):S120–S126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15942878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giles J.A., Falconio J., Yuenger J.D., Zenilman J.M., Dan M., Bash M.C. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis. 2004;189(11):2085–2093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15143477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindbäck E., Rahman M., Jalal S., Wretlind B. Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae. APMIS Acta Pathol Microbiol Immunol Scand. 2002;110(9):651–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12529019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka M., Nakayama H., Haraoka M., Saika T. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol. 2000;38(2):521–525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86137</ArticleId>
            <ArticleId IdType="pubmed">10655338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Neeling A.J., van Santen-Verheuvel M., Spaargaren J., Willems R.J. Antimicrobial resistance of Neisseria gonorrhoeae and emerging ciprofloxacin resistance in the Netherlands, 1991 to 1998. Antimicrob Agents Chemother. 2000;44(11):3184–3185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC101628</ArticleId>
            <ArticleId IdType="pubmed">11036048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavroidi A., Tzouvelekis L.S., Tassios P.T., Flemetakis A., Daniilidou M., Tzelepi E. Characterization of Neisseria gonorrhoeae strains with decreased susceptibility to fluoroquinolones isolated in Greece from 1996 to 1999. J Clin Microbiol. 2000;38(9):3489–3491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC87415</ArticleId>
            <ArticleId IdType="pubmed">10970412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su X., Lind I. Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998. Antimicrob Agents Chemother. 2001;45(1):117–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC90248</ArticleId>
            <ArticleId IdType="pubmed">11120953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(37):833–837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11012233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC Increases in fluoroquinolone-resistant Neisseria gonorrhoeae – Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51(46):1041–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12487525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Shafer W.M. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4135894</ArticleId>
            <ArticleId IdType="pubmed">24982323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poehlsgaard J., Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005;3(11):870–881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16261170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belkacem A., Jacquier H., Goubard A. Molecular epidemiology and mechanisms of resistance of azithromycin-resistant Neisseria gonorrhoeae isolated in France during 2013–14. J Antimicrob Chemother. 2016;71(9):2471–2478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27301565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen V.G., Seah C., Martin I., Melano R.G. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada. Antimicrob Agents Chemother. 2014;58(5):2528–2534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3993249</ArticleId>
            <ArticleId IdType="pubmed">24514092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urlaub H., Kruft V., Bischof O., Müller E.C., Wittmann-Liebold B. Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995;14(18):4578–4588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC394550</ArticleId>
            <ArticleId IdType="pubmed">7556101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tait-Kamradt A., Davies T., Cronan M., Jacobs M.R., Appelbaum P.C., Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 2000;44(8):2118–2125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC90022</ArticleId>
            <ArticleId IdType="pubmed">10898684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zengel J.M., Jerauld A., Walker A., Wahl M.C., Lindahl L. The extended loops of ribosomal proteins L4 and L22 are not required for ribosome assembly or L4-mediated autogenous control. RNA. 2003;9(10):1188–1197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1370483</ArticleId>
            <ArticleId IdType="pubmed">13130133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts M.C., Chung W.O., Roe D. Erythromycin-resistant Neisseria gonorrhoeae and oral commensal Neisseria spp. carry known rRNA methylase genes. Antimicrob Agents Chemother. 1999;43(6):1367–1372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC89280</ArticleId>
            <ArticleId IdType="pubmed">10348754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demczuk W., Martin I., Peterson S. Genomic epidemiology and molecular resistance mechanisms of azithromycin-resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. J Clin Microbiol. 2016;54(5):1304–1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4844716</ArticleId>
            <ArticleId IdType="pubmed">26935729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chisholm S.A., Dave J., Ison C.A. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother. 2010;54(9):3812–3816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2935028</ArticleId>
            <ArticleId IdType="pubmed">20585125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bercot B., Belkacem A., Goubard A. High-level azithromycin-resistant Neisseria gonorrhoeae clinical isolate in France, March 2014. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2014;19(44)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25394255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevens K., Zaia A., Tawil S. Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Australia. J Antimicrob Chemother. 2015;70(4):1267–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25480491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galarza P.G., Alcalá B., Salcedo C. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex Transm Dis. 2009;36(12):787–788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19734823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chisholm S.A., Neal T.J., Alawattegama A.B., Birley H.D.L., Howe R.A., Ison C.A. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother. 2009;64(2):353–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19468025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz A.R., Komeya A.Y., Soge O.O. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54(6):841–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6746146</ArticleId>
            <ArticleId IdType="pubmed">22184617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni C., Xue J., Zhang C., Zhou H., van der Veen S. High prevalence of Neisseria gonorrhoeae with high-level resistance to azithromycin in Hangzhou, China. J Antimicrob Chemother. 2016;71(8):2355–2357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27090631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chisholm S.A., Wilson J., Alexander S. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect. 2016;92(5):365–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26601852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobsson S., Golparian D., Cole M. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC &gt;2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014. J Antimicrob Chemother. 2016;71(11):3109–3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27432597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry P.M., Klausner J.D. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother. 2009;10(4):555–577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2657229</ArticleId>
            <ArticleId IdType="pubmed">19284360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka M., Nakayama H., Tunoe H. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother Off J Jpn Soc Chemother. 2002;8(1):81–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11957125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Golparian D., Syversen G., Vestrheim D.F., Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2010;15(47)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21144442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Golparian D., Stary A., Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011;16(43)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22085601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Golparian D., Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011;16(6)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21329645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ameyama S., Onodera S., Takahata M. Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother. 2002;46(12):3744–3749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC132769</ArticleId>
            <ArticleId IdType="pubmed">12435671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M., Golparian D., Nicholas R., Ohnishi M., Gallay A., Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273–1280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3294892</ArticleId>
            <ArticleId IdType="pubmed">22155830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cámara J., Serra J., Ayats J. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67(8):1858–1860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22566592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahra M.M., Ryder N., Whiley D.M. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850–1851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25372111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC . 2010. Sexually Transmitted Diseases Treatment Guidelines.https://www.cdc.gov/mmwr/preview/mmwrhtmL/rr5912a1.htm Accessed 02.06.17.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
